Trial
NCT02667418
Optimal Treatment for Recurrent Clostridium Difficile
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
VA Office of Research and Development
Collaborators
—
Condition
Clostridium
Intervention
Fidaxomicin
Why stopped
The study sponsor stopped the trial early after enrolling 308 of the target sample size because of a slower than expected recruitment rate.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-15